Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284784 · ClinicalTrials.gov registry record · Phase 2
A Study of Buntanetap in Participants With PD
A Phase 2 study of Parkinsons Disease (PD) and Deep Brain Stimulation, sponsored by Annovis Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT07284784: Recruiting Phase 2 study of Parkinsons Disease (PD) and Deep Brain Stimulation, sponsored by Annovis Bio.
NCT07284784 is a Phase 2 study of Parkinsons Disease (PD) and Deep Brain Stimulation that is actively recruiting participants, run by Annovis Bio. The registered enrollment target is 500 participants, above the 93-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (438% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07284784, a Phase 2 study of Parkinsons Disease (PD) and Deep Brain Stimulation, is actively recruiting participants, sponsored by Annovis Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.
Primary Outcome
Safety assessments of participants with PD receiving treatment with buntanetap
Conditions Studied
Interventions
- DRUG buntanetap/posiphen
Study Locations (20)
Florida
- First Choice Neurology - Aventura Neurologic Associates - Aventura
- Arrow Clinical Trials - Daytona Beach
- Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU - DeLand
- Renstar Medical Research - Ocala
- University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di - Tampa
- Conquest Research - Winter Park
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research - Sun City
California
- Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office - Fountain Valley
Colorado
- Cenexel Rocky Mountain Clinical Research - Englewood
Connecticut
- New England Institute for Clinical Research (Ki Health Partners) - Stamford
Georgia
- iResearch Atlanta - Decatur
Indiana
- Josephson Wallack Munshower Neurology, P.C. - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-01-09 |
| Est. Completion | 2029-11 |
| Phase | Phase 2 |
What NCT07284784 shows while recruiting
NCT07284784 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 93-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (438% higher).
The record links to 2 conditions, with Parkinsons Disease (PD) appearing as the primary indexed condition, and to 1 intervention - of which buntanetap/posiphen is the first listed.
NCT07284784 names 20 study sites across 15 states, led by Florida, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT07284784 about?
NCT07284784 is a clinical study titled "A Study of Buntanetap in Participants With PD". This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical tri...
What is the current status of trial NCT07284784?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2026-01-09. Estimated completion is 2029-11.
What conditions does trial NCT07284784 study?
This clinical trial studies the following conditions: Parkinsons Disease (PD), Deep Brain Stimulation.
What interventions are being tested in trial NCT07284784?
The interventions under investigation include: buntanetap/posiphen (DRUG).
Who is sponsoring clinical trial NCT07284784?
This trial is sponsored by Annovis Bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07284784 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinsons Disease (PD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07284784's enrollment target sits among peer trials
500 1st of 19 higher than 19 of 19 other Parkinsons Disease (PD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinsons Disease (PD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of NE3107 in Early Parkinson's
RECRUITING · Phase 2
-
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
RECRUITING · Phase 2
-
Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD
RECRUITING · NA
-
Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations
RECRUITING · NA
-
Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
RECRUITING · Phase 1
-
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI